377 related articles for article (PubMed ID: 16158069)
61. Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.
Vigneault P; Bourgault S; Kaddar N; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
Eur J Pharmacol; 2012 Apr; 681(1-3):68-74. PubMed ID: 22366430
[TBL] [Abstract][Full Text] [Related]
62. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
Farkas AS; Nattel S
Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
[TBL] [Abstract][Full Text] [Related]
63. The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability.
Roche M; Renauleaud C; Ballet V; Doubovetzky M; Guillon JM
J Pharmacol Toxicol Methods; 2010; 61(3):238-50. PubMed ID: 20117224
[TBL] [Abstract][Full Text] [Related]
64. Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration.
Vigneault P; Pilote S; Patoine D; Simard C; Drolet B
Pharmacol Res; 2012 Jul; 66(1):60-5. PubMed ID: 22465688
[TBL] [Abstract][Full Text] [Related]
65. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
Lu HR; Vlaminckx E; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2005; 52(1):90-105. PubMed ID: 15978848
[TBL] [Abstract][Full Text] [Related]
66. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.
Schneider J; Hauser R; Andreas JO; Linz K; Jahnel U
Eur J Pharmacol; 2005 Apr; 512(1):53-60. PubMed ID: 15814090
[TBL] [Abstract][Full Text] [Related]
67. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo.
Carlsson L; Andersson B; Linhardt G; Löfberg L
J Cardiovasc Pharmacol; 2009 Jul; 54(1):82-9. PubMed ID: 19528812
[TBL] [Abstract][Full Text] [Related]
68. Cardiovascular safety assessments in the conscious telemetered dog: utilisation of super-intervals to enhance statistical power.
Sivarajah A; Collins S; Sutton MR; Regan N; West H; Holbrook M; Edmunds N
J Pharmacol Toxicol Methods; 2010; 62(1):12-9. PubMed ID: 20570743
[TBL] [Abstract][Full Text] [Related]
69. Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines.
Couderc JP; Garnett C; Li M; Handzel R; McNitt S; Xia X; Polonsky S; Zareba W
Ann Noninvasive Electrocardiol; 2011 Jan; 16(1):13-24. PubMed ID: 21251129
[TBL] [Abstract][Full Text] [Related]
70. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
[TBL] [Abstract][Full Text] [Related]
71. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.
Joshi A; Dimino T; Vohra Y; Cui C; Yan GX
J Electrocardiol; 2004; 37 Suppl():7-14. PubMed ID: 15534787
[TBL] [Abstract][Full Text] [Related]
72. Moxifloxacin and torsade de pointes.
Dale KM; Lertsburapa K; Kluger J; White CM
Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
[TBL] [Abstract][Full Text] [Related]
73. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
74. Azithromycin Causes a Novel Proarrhythmic Syndrome.
Yang Z; Prinsen JK; Bersell KR; Shen W; Yermalitskaya L; Sidorova T; Luis PB; Hall L; Zhang W; Du L; Milne G; Tucker P; George AL; Campbell CM; Pickett RA; Shaffer CM; Chopra N; Yang T; Knollmann BC; Roden DM; Murray KT
Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408648
[TBL] [Abstract][Full Text] [Related]
75. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis.
Dumotier BM; Deurinck M; Yang Y; Traebert M; Suter W
Pharmacol Ther; 2008 Aug; 119(2):152-9. PubMed ID: 18462801
[TBL] [Abstract][Full Text] [Related]
76. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
[TBL] [Abstract][Full Text] [Related]
77. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
Stylianou A; Roger J; Stephens K
J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
[TBL] [Abstract][Full Text] [Related]
78. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
Matthys G; Park JW; McGuire S; Wire MB; Zhang J; Bowen C; Williams D; Jenkins JM; Peng B
Br J Clin Pharmacol; 2010 Jul; 70(1):24-33. PubMed ID: 20642544
[TBL] [Abstract][Full Text] [Related]
79. Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.
Park E; Gintant GA; Bi D; Kozeli D; Pettit SD; Pierson JB; Skinner M; Willard J; Wisialowski T; Koerner J; Valentin JP
Br J Pharmacol; 2018 Feb; 175(4):606-617. PubMed ID: 29181850
[TBL] [Abstract][Full Text] [Related]
80. Hypaconitine-induced QT prolongation mediated through inhibition of KCNH2 (hERG) potassium channels in conscious dogs.
Xie S; Jia Y; Liu A; Dai R; Huang L
J Ethnopharmacol; 2015 May; 166():375-9. PubMed ID: 25800797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
